BCL2L11 and neoplasm: In agreement with in vitro studies, in tumours treated with alvocidib we observed downregulation of the marker of proliferation Ki67 as well of MYC, Survivin and MCL‐1, and upregulation of BIM and p21(Figs 6E and F, and EV5B and C).